Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
This study evaluated a difficult-to-treat Crohn's disease patient population
Subscribe To Our Newsletter & Stay Updated
